drugset / Trial / NCT01428726
A Phase IIa Study of NT-KO-003 for Multiple Sclerosis
Phase 2
Completed
99 enrolled
Neurotec Pharma
Advancell - Advanced In Vitro Cell Technologies, S.A. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of the study is to assess the efficacy and safety of NT-KO-003 in the treatment of relapsing remitting multiple sclerosis, comparing two doses versus placebo.
Timeline
- Start
- 2011-06
- Primary completion
- 2014-01
- Completion
- 2014-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NT-KO-003 | Unknown | — | Oral |